Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -51.72% | -35.70% | 24.12% | 29.08% | -19.92% |
| Total Depreciation and Amortization | 15.79% | 3.56% | 36.16% | 27.25% | 382.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -148.88% | -122.63% | -12.64% | -18.31% | -2.98% |
| Change in Net Operating Assets | 59.28% | 63.57% | 267.94% | 243.99% | -513.46% |
| Cash from Operations | -50.09% | -34.24% | 37.89% | 41.95% | -35.23% |
| Capital Expenditure | 89.74% | 90.80% | 79.80% | 81.23% | -48.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -98.37% | -98.55% | 103.41% | 103.19% | 93,666.33% |
| Cash from Investing | -98.40% | -98.57% | 103.23% | 103.02% | 81,866.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -200.77% | -200.77% | -- |
| Issuance of Common Stock | 175.00% | 175.00% | 103,200.00% | 103,200.00% | -99.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,530.61% | -2,267.92% | 1,631.59% | 1,518.21% | -99.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.27% | -161.95% | 165.08% | 160.82% | -51.73% |